Molecular Partners (NASDAQ:MOLN) Shares Up 2.2% – What’s Next?

Shares of Molecular Partners AG (NASDAQ:MOLN) were up 2.2% on Monday . The company traded as high as $3.89 and last traded at $3.89. Approximately 657 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 20,207 shares. The stock had previously closed at $3.80.

Wall Street Analysts Forecast Growth

Separately, Lifesci Capital began coverage on shares of Molecular Partners in a research note on Tuesday, March 11th. They set an “outperform” rating and a $12.00 target price on the stock.

Molecular Partners Stock Up 2.2%

The business’s 50-day moving average is $3.89 and its two-hundred day moving average is $4.63. The stock has a market capitalization of $156.86 million, a price-to-earnings ratio of -1.81 and a beta of 1.11.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. As a group, analysts forecast that Molecular Partners AG will post -1.93 EPS for the current fiscal year.

Institutional Trading of Molecular Partners

A hedge fund recently raised its stake in Molecular Partners stock. BVF Inc. IL increased its position in shares of Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,353,968 shares of the company’s stock after buying an additional 910,747 shares during the quarter. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent reporting period. 26.55% of the stock is currently owned by institutional investors.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.